Figure 1
From: Radiation sterilisation of cultured human brain tumour cells for clinical immune tumour therapy
(A) Surviving ratio from 3H-thymidine incorporation as a function of absorbed dose for the irradiated cells of patients GM 1, GM 2, GM 3, GC 1 (of malignant karyotype) and N1 (of normal karyotype). (B) Surviving fractions from MTT assays as a function of absorbed dose for the irradiated cells from patients GMB 1, GMB 2, GMB 3, GC (of malignant karyotype) and of normal karyotype. Keys to the abbreviations are given under the paragraph ‘Karyotyping’.
